Creating functional human tissues on demand via 3D bio-printing and tissue engineering.
Aspect Biosystems is a privately held biotechnology company pioneering micro-fluidic 3D bio-printing of living human tissue. The company’s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to enable the creation of living human tissues for medical research, therapeutic discovery, and regenerative medicine products. Their vision is a future in which drugs are developed without the use of animals, doctors know how a patient will react to a drug before prescribing it, and lifesaving transplant organs are created, not harvested. In 2018, BIOTECanada recognized Aspect as the Gold Leaf Award Winner for Emerging Company of the Year.
Currently Operating in Nine Regions
June 5, 2019
Aspect Biosystems Partners with Merck, GSK, and McGill University to Enable Development of Immuno-Oncology Therapeutics
This $2.2M project is made possible by contributions from CQDM, CCS, Merck, GSK, Aspect Biosystems, and McGill University.
July 21, 2020
Competitive spirit has driven engineer-turned-entrepreneur Tamer Mohamed’s success with Aspect Biosystems
January 9, 2020
Aspect Biosystems, a biotechnology company advancing microfluidic 3D bioprinting of human tissues, raised US $20m in Series A financing. Investors include Pangaea Ventures, Pallasite Ventures,...
Work at Aspect Biosystems
More Ventures in Health
Get the Unreasonable Newsletter
Get twice-monthly updates on Aspect Biosystems and over 312 other ventures working to solve the world's toughest problems.